Thank you very much, Heidi, and welcome to everyone joining us for this Q4 and full year ‘24 earnings call. My name is Florian Schraeder, I'm Head of Investor Relation at Merck. I'm delighted to ...

Electronics EBITDA Pre Margin (Q4 2024): 25.6%. Guidance for 2025 Sales: EUR21.5 billion to EUR22.9 billion. Guidance for 2025 EBITDA Pre: EUR6.1 billion to EUR6.6 billion. Merck KGaA (MKGAF ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

Merck & Company Inc. (MRK) reported its financial results for the full year 2024, showing a slight increase in net sales and a notable improvement in operating cash flow. The company’s stock ...

Perhaps the biggest upset was the failure of GlaxoSmithKline and Merck KGaA’s bintrafusp alfa ... Biogen needs to find new revenues soon, however as Q4 results showed flat revenues for its ...

Q4 turnover was down from last year’s total ... Full-year 2012 worldwide sales for Merck were down 2% to US $47.3 billion, compared to full-year 2011. In August 2012, Merck lost market ...

Merck & Company Inc. (MRK) reported its financial results for the full year 2024, showing a slight increase in net sales and a notable improvement in operating cash flow. The company’s stock ...

Electronics EBITDA Pre Margin (Q4 2024): 25.6%. Guidance for 2025 Sales: EUR21.5 billion to EUR22.9 billion. Guidance for 2025 EBITDA Pre: EUR6.1 billion to EUR6.6 billion. Merck KGaA (MKGAF) ...